|Bid||2.2200 x 800|
|Ask||2.3000 x 1100|
|Day's Range||2.1800 - 2.3000|
|52 Week Range||1.7900 - 22.1650|
|Beta (5Y Monthly)||0.01|
|PE Ratio (TTM)||N/A|
|Earnings Date||Dec 15, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
LAS VEGAS, May 23, 2022--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has initiated the first in a series of studies to test the ability of its pancreatic cancer therapy to treat malignant ascites. The initiation of this first study was made possible after PharmaCyte’s successful production of a Master Cell Bank as we
Iroquois Capital Management, LLC (together with its affiliates, "Iroquois"), one of the largest shareholders of PharmaCyte Biotech, Inc. ("PMCB" or the "Company") (NASDAQ:PMCB) with beneficial ownership of approximately 5.1% of the outstanding common stock of the Company, today announced that it has delivered a letter to the Company's Board of Directors.
LAS VEGAS, April 27, 2022--PharmaCyte's management team is attending the 15th International Conference on Advanced Technologies and Treatment for Diabetes in Barcelona, Spain.